Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

2019-02-04

The Pharmacogenomics Journal , Volume 19 - Issue 5 p. 473- 479

Additional Metadata
Persistent URL	doi.org/10.1038/s41397-019-0079-z, hdl.handle.net/1765/121192
Journal	The Pharmacogenomics Journal
Rights	no subscription
Organisation	Rheumatology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Verboom, MC, Kloth, J., Swen, J., Sleijfer, S., Reyners, AK, Steeghs, N., … Guchelaar, H. J. (2019). Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. The Pharmacogenomics Journal, 19(5), 473–479. doi:10.1038/s41397-019-0079-z

Publication